XNAS · AIDX
0.00% · $0.0000 · Vol Not reported
Market closed · last close shown
20/20 Biolabs, Inc. Common Stock

20/20 Biolabs, Inc. Common Stock

SERVICES-TESTING LABORATORIES
$0.3435
Card
Relationship Map

Follow $AIDX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $AIDX by email

Veridion Score

BETALOW CONF · 5 of 6 factors measuredMethodology
Earnings absence reason unknown
AIDX
20/20 Biolabs, Inc. Common Stock
Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

46/ 100
Veridion Score
Middle range · LOW confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5 of 6 factors measured · Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is AIDX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading AIDX catalysts
About 20/20 Biolabs, Inc. Common Stock
SERVICES-TESTING LABORATORIES
Listed since
2026
Employees
14
Country
US

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.3435
Last session
Day high
$0.3435
Last session
Day low
$0.3435
Last session
Previous close
$0.3435
52W high
$23.85
-98.56% from high
52W low
$0.3435
0% of range
Market cap
$4.4M
Beta
-0.10
Shares out
12.8M
Avg volume
64.5K
VWAP
$0.3435
Last session
Price history computed in-house
1W
-15.99%
1M
-40.56%
3M
-41.69%
SMA 50 $0.4890 · below
SMA 200 Not reported · Not reported
52W position 0%

AIDX overview

Veridion Score
46
Registered · 2026-10-07
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around AIDX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading AIDX Form 4 filings
Public disclosures

Congress activity in AIDX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

AIDX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for AIDX in this window.
Lobbying spend

AIDX lobbying filings, year to date.

Registered lobbying filings matched to 20/20 Biolabs, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for AIDX in this window.
Loading news for AIDX
Analyst ratings
Sovereign unlock shows live analyst consensus for AIDX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.